Details of the Drug

General Information of Drug (ID: DM9BI7M)

Drug Name

Duloxetine

Synonyms

Yentreve; LY 248686; Cymbalta (TN); Duloxetine (INN); Duloxetine [INN:BAN]; Yentreve (TN); Duloxetine, (+)-isomer; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; (S)-Duloxetine; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Major depressive disorder	6A70.3	Approved	[2]
Stress urinary incontinence	MF50.20	Approved	[2]
Traumatic brain injury	NA07.Z	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

297.4

Logarithm of the Partition Coefficient (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 6 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 50% [3]
Clearance: The clearance of drug is 57-114 L/h [3]
Elimination: About 70% of duloxetine is excreted in the urine mainly as conjugated metabolites [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 hours [5]
Metabolism: The drug is metabolized via the CYP1A2 and CYP2D6 with the former being the greater contributor []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.882 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.04% [5]
Vd: The volume of distribution (Vd) of drug is 1620-1800 L [3]

Chemical Identifiers

Formula: C18H19NOS
IUPAC Name: (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine
Canonical SMILES: CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
InChI: InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
InChIKey: ZEUITGRIYCTCEM-KRWDZBQOSA-N

Cross-matching ID

PubChem CID: 60835
ChEBI ID: CHEBI:36795
CAS Number: 116539-59-4
DrugBank ID: DB00476
TTD ID: D01AXB
VARIDT ID: DR01001
INTEDE ID: DR0554
ACDINA ID: D00220

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[7]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[8]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)_{Main DME}	DEJGDUW	CP1A2_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[9]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[9]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Gene/Protein Processing	[10]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Protein Interaction/Cellular Processes	[10]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[11]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Gene/Protein Processing	[12]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Gene/Protein Processing	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

06 Mental, behavioural or neurodevelopmental disorder

Disease Class

ICD-11: 6A20 Schizophrenia

The Studied Tissue

Pre-frontal cortex

The Studied Disease

Major depressive disorder [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Norepinephrine transporter (NET)	DTT	SLC6A2	7.05E-01	7.02E-03	0.07
Serotonin transporter (SERT)	DTT	SLC6A4	1.17E-01	0.07	0.59
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.68E-01	3.64E-02	2.72E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.83E-01	2.32E-03	1.53E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Duloxetine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Duloxetine and Sertraline.	Depression [6A70-6A7Z]	[14]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Duloxetine and Trimipramine.	Depression [6A70-6A7Z]	[14]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Duloxetine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[14]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of Duloxetine and Nortriptyline.	Depression [6A70-6A7Z]	[14]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Duloxetine and Vilazodone.	Depression [6A70-6A7Z]	[14]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Duloxetine and Nefazodone.	Depression [6A70-6A7Z]	[14]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Duloxetine and Paroxetine.	Depression [6A70-6A7Z]	[14]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Duloxetine and Selegiline.	Depression [6A70-6A7Z]	[15]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Duloxetine and Vortioxetine.	Depression [6A70-6A7Z]	[14]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Duloxetine and Isocarboxazid.	Depression [6A70-6A7Z]	[15]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Duloxetine and Milnacipran.	Depression [6A70-6A7Z]	[14]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Duloxetine and Escitalopram.	Depression [6A70-6A7Z]	[14]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Duloxetine and Tranylcypromine.	Depression [6A70-6A7Z]	[15]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Duloxetine and Desvenlafaxine.	Depression [6A70-6A7Z]	[14]
OPC-34712	DMHG57U	Major	Decreased metabolism of Duloxetine caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[16]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Duloxetine and Phenelzine.	Depression [6A70-6A7Z]	[15]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Duloxetine and Clomipramine.	Depression [6A70-6A7Z]	[14]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Duloxetine and Trazodone.	Depression [6A70-6A7Z]	[14]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of Duloxetine and Amoxapine.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Duloxetine and Doxepin.	Depression [6A70-6A7Z]	[14]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Duloxetine and Maprotiline.	Depression [6A70-6A7Z]	[14]
-----------


⏷ Show the Full List of 21 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Duloxetine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[17]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[18]
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Duloxetine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[19]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Duloxetine caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[20]
Epinephrine	DM3KJBC	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Epinephrine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[18]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Duloxetine caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[21]
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Duloxetine and Inotersen.	Amyloidosis [5D00]	[22]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Duloxetine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[23]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of Duloxetine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[14]
Methylphenobarbital	DMDSWAG	Moderate	Antagonize the effect of Duloxetine when combined with Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[24]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Duloxetine and Cilostazol.	Arterial occlusive disease [BD40]	[22]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Duloxetine and Levalbuterol.	Asthma [CA23]	[18]
Terbutaline	DMD4381	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Terbutaline.	Asthma [CA23]	[18]
Pirbuterol	DMI5678	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Pirbuterol.	Asthma [CA23]	[18]
Ephedrine	DMMV0KW	Moderate	Additive hypertensive effects by the combination of Duloxetine and Ephedrine.	Asthma [CA23]	[18]
Salbutamol	DMN9CWF	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Salbutamol.	Asthma [CA23]	[18]
Formoterol	DMSOURV	Moderate	Additive hypertensive effects by the combination of Duloxetine and Formoterol.	Asthma [CA23]	[18]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Duloxetine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[25]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Duloxetine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Obeticholic acid	DM3Q1SM	Moderate	Decreased metabolism of Duloxetine caused by Obeticholic acid mediated inhibition of CYP450 enzyme.	Autoimmune liver disease [DB96]	[25]
Ciprofloxacin XR	DM2NLS9	Major	Decreased metabolism of Duloxetine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Duloxetine and Linezolid.	Bacterial infection [1A00-1C4Z]	[26]
Norfloxacin	DMIZ6W2	Moderate	Decreased metabolism of Duloxetine caused by Norfloxacin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Rabeprazole	DMMZXIW	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Rabeprazole.	Bacterial infection [1A00-1C4Z]	[18]
Retigabine	DMGNYIH	Moderate	Antagonize the effect of Duloxetine when combined with Retigabine.	Behcet disease [4A62]	[24]
Lamotrigine	DM8SXYG	Moderate	Antagonize the effect of Duloxetine when combined with Lamotrigine.	Bipolar disorder [6A60]	[24]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Duloxetine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[27]
Tamoxifen	DMLB0EZ	Major	Decreased metabolism of Duloxetine caused by Tamoxifen mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Duloxetine and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[29]
Pseudoephedrine	DMIVJ0D	Moderate	Additive hypertensive effects by the combination of Duloxetine and Pseudoephedrine.	Breathing abnormality [MD11]	[18]
Mannitol	DMSCDY9	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Mannitol.	Bronchiectasis [CA24]	[30]
Niclosamide	DMJAGXQ	Moderate	Decreased metabolism of Duloxetine caused by Niclosamide mediated inhibition of CYP450 enzyme.	Cestodes infection [1F70-1F76]	[25]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Duloxetine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Vilanterol	DMF5EK1	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Salmeterol	DMIEU69	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Indacaterol	DMQJHR7	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Arformoterol	DMYM974	Moderate	Additive hypertensive effects by the combination of Duloxetine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of bleeding by the combination of Duloxetine and Phenylbutazone.	Chronic pain [MG30]	[22]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Duloxetine and Dihydrocodeine.	Chronic pain [MG30]	[31]
Ketoprofen	DMRKXPT	Moderate	Increased risk of bleeding by the combination of Duloxetine and Ketoprofen.	Chronic pain [MG30]	[22]
Levetiracetam	DMTGDN8	Moderate	Antagonize the effect of Duloxetine when combined with Levetiracetam.	Chronic pain [MG30]	[24]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Duloxetine and Levomilnacipran.	Chronic pain [MG30]	[14]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Duloxetine and Regorafenib.	Colorectal cancer [2B91]	[22]
Isoproterenol	DMK7MEY	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Isoproterenol.	Conduction disorder [BC63]	[18]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Duloxetine and Olopatadine.	Conjunctiva disorder [9A60]	[32]
Alfentanil	DMVO0UB	Major	Additive serotonergic effects by the combination of Duloxetine and Alfentanil.	Corneal disease [9A76-9A78]	[14]
Remifentanil	DMZTXCH	Major	Additive serotonergic effects by the combination of Duloxetine and Remifentanil.	Corneal disease [9A76-9A78]	[14]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Duloxetine and Ardeparin.	Coronary thrombosis [BA43]	[22]
Dextromethorphan	DMUDJZM	Major	Additive serotonergic effects by the combination of Duloxetine and Dextromethorphan.	Cough [MD12]	[14]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Duloxetine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[25]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Duloxetine and Danaparoid.	Deep vein thrombosis [BD71]	[22]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Duloxetine and Rivaroxaban.	Deep vein thrombosis [BD71]	[22]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Duloxetine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[18]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[18]
LEVONORDEFRIN	DMWDJ0H	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and LEVONORDEFRIN.	Discovery agent [N.A.]	[18]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Duloxetine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[14]
Zonisamide	DM0DTF7	Moderate	Antagonize the effect of Duloxetine when combined with Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Felbamate	DM1V5ZS	Moderate	Antagonize the effect of Duloxetine when combined with Felbamate.	Epilepsy/seizure [8A61-8A6Z]	[24]
Oxcarbazepine	DM5PU6O	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[24]
Mephenytoin	DM5UGDK	Moderate	Antagonize the effect of Duloxetine when combined with Mephenytoin.	Epilepsy/seizure [8A61-8A6Z]	[24]
Methsuximide	DM6L5VO	Moderate	Antagonize the effect of Duloxetine when combined with Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Ethosuximide	DMDZ9LT	Moderate	Antagonize the effect of Duloxetine when combined with Ethosuximide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Tiagabine	DMKSQG0	Moderate	Antagonize the effect of Duloxetine when combined with Tiagabine.	Epilepsy/seizure [8A61-8A6Z]	[24]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Duloxetine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[18]
Phenacemide	DMOHS9P	Moderate	Antagonize the effect of Duloxetine when combined with Phenacemide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Paramethadione	DMR5ZUP	Moderate	Antagonize the effect of Duloxetine when combined with Paramethadione.	Epilepsy/seizure [8A61-8A6Z]	[24]
Lacosamide	DMVM6QR	Moderate	Antagonize the effect of Duloxetine when combined with Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Rufinamide	DMWE60C	Moderate	Antagonize the effect of Duloxetine when combined with Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Ethotoin	DMXWOCP	Moderate	Antagonize the effect of Duloxetine when combined with Ethotoin.	Epilepsy/seizure [8A61-8A6Z]	[24]
Vigabatrin	DMYT0OG	Moderate	Antagonize the effect of Duloxetine when combined with Vigabatrin.	Epilepsy/seizure [8A61-8A6Z]	[24]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[24]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Cannabidiol.	Epileptic encephalopathy [8A62]	[33]
Diphenhydramine	DMKQTBA	Moderate	Decreased metabolism of Duloxetine caused by Diphenhydramine mediated inhibition of CYP450 enzyme.	Episodic vestibular syndrome [AB31]	[18]
Mephentermine	DMFJH5Q	Moderate	Additive hypertensive effects by the combination of Duloxetine and Mephentermine.	Essential hypertension [BA00]	[18]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Benzthiazide.	Essential hypertension [BA00]	[30]
Oxymetazoline	DM8ZXT6	Moderate	Additive hypertensive effects by the combination of Duloxetine and Oxymetazoline.	Eyelid inflammatory disorder [9A02]	[18]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of bleeding by the combination of Duloxetine and Mefenamic acid.	Female pelvic pain [GA34]	[22]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Duloxetine and Tazemetostat.	Follicular lymphoma [2A80]	[22]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Duloxetine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[18]
Tolterodine	DMSHPW8	Minor	Decreased metabolism of Duloxetine caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[34]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Duloxetine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[18]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Duloxetine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[18]
Dexlansoprazole	DM1DBV5	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[18]
Nizatidine	DMGFV3Z	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Nizatidine.	Gastro-oesophageal reflux disease [DA22]	[18]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Duloxetine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[25]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Duloxetine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[22]
Acetazolamide	DM1AF5U	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Acetazolamide.	Glaucoma [9C61]	[30]
Methazolamide	DM7J2TA	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Methazolamide.	Glaucoma [9C61]	[30]
Dichlorphenamide	DMH7IDQ	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Dichlorphenamide.	Glaucoma [9C61]	[30]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Duloxetine and Sulfinpyrazone.	Gout [FA25]	[22]
Ergotamine	DMKR3C5	Major	Additive serotonergic effects by the combination of Duloxetine and Ergotamine.	Headache [8A80-8A84]	[14]
Dobutamine	DMD1B8Z	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Dobutamine.	Heart failure [BD10-BD1Z]	[18]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Duloxetine caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[18]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[30]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Furosemide.	Heart failure [BD10-BD1Z]	[30]
Amiloride	DMRTSGP	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Amiloride.	Heart failure [BD10-BD1Z]	[30]
Bumetanide	DMRV7H0	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Bumetanide.	Heart failure [BD10-BD1Z]	[30]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[30]
Tetrahydrozoline	DMT57WC	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Tetrahydrozoline.	Herpes simplex infection [1F00]	[18]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Duloxetine caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[25]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Duloxetine and Procarbazine.	Hodgkin lymphoma [2B30]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[35]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Duloxetine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Duloxetine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Duloxetine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Duloxetine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[37]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Duloxetine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[38]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Duloxetine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[39]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Duloxetine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[18]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Duloxetine caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[25]
Pindolol	DMD2NV7	Moderate	Decreased metabolism of Duloxetine caused by Pindolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[18]
Methoxamine	DMF5XQH	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Methoxamine.	Hypertension [BA00-BA04]	[18]
Indapamide	DMGN1PW	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Indapamide.	Hypertension [BA00-BA04]	[30]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Trichlormethiazide.	Hypertension [BA00-BA04]	[30]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[30]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Duloxetine and Dipyridamole.	Hypertension [BA00-BA04]	[22]
Metaraminol	DMWIX23	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Metaraminol.	Hypotension [BA20-BA21]	[18]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Duloxetine caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[33]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Duloxetine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[25]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of bleeding by the combination of Duloxetine and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[29]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Duloxetine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[40]
Propiomazine	DMKY8V1	Moderate	Decreased metabolism of Duloxetine caused by Propiomazine mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Duloxetine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[41]
Naphazoline	DMJFZDL	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Naphazoline.	Itching [1F28-1G07]	[18]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Methotrexate.	Leukaemia [2A60-2B33]	[33]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Duloxetine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[18]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Duloxetine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[18]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Duloxetine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Duloxetine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Halofantrine	DMOMK1V	Moderate	Decreased metabolism of Duloxetine caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[18]
Chloroquine	DMSI5CB	Moderate	Decreased metabolism of Duloxetine caused by Chloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[18]
Hydroxychloroquine	DMSIVND	Moderate	Decreased metabolism of Duloxetine caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[18]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Duloxetine caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[25]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[43]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Idelalisib.	Mature B-cell leukaemia [2A82]	[44]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Duloxetine and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[22]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Clofarabine.	Mature B-cell lymphoma [2A85]	[45]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Duloxetine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[22]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Duloxetine and Ponatinib.	Mature B-cell lymphoma [2A85]	[22]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Duloxetine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[25]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Duloxetine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[46]
Propranolol	DM79NTF	Moderate	Decreased metabolism of Duloxetine caused by Propranolol mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[18]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Duloxetine and Almogran.	Migraine [8A80]	[14]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Duloxetine and Frovatriptan.	Migraine [8A80]	[14]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Duloxetine and Rizatriptan.	Migraine [8A80]	[14]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Duloxetine and Naratriptan.	Migraine [8A80]	[14]
Sumatriptan	DMVYXR8	Major	Additive serotonergic effects by the combination of Duloxetine and Sumatriptan.	Migraine [8A80]	[14]
Exjade	DMHPRWG	Moderate	Increased risk of bleeding by the combination of Duloxetine and Exjade.	Mineral absorption/transport disorder [5C64]	[22]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Duloxetine and Flibanserin.	Mood disorder [6A60-6E23]	[47]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Duloxetine and Panobinostat.	Multiple myeloma [2A83]	[22]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Duloxetine and Thalidomide.	Multiple myeloma [2A83]	[48]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Duloxetine and Ozanimod.	Multiple sclerosis [8A40]	[15]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Duloxetine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Duloxetine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Duloxetine and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[22]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Duloxetine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[18]
Dasatinib	DMJV2EK	Moderate	Increased risk of bleeding by the combination of Duloxetine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[22]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Duloxetine and Prasugrel.	Myocardial infarction [BA41-BA43]	[22]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Duloxetine and Vorapaxar.	Myocardial infarction [BA41-BA43]	[22]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Duloxetine and Tirofiban.	Myocardial infarction [BA41-BA43]	[22]
Promethazine	DM6I5GR	Moderate	Decreased metabolism of Duloxetine caused by Promethazine mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[18]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Duloxetine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[49]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Duloxetine and Granisetron.	Nausea/vomiting [MD90]	[38]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Duloxetine and Dolasetron.	Nausea/vomiting [MD90]	[38]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Duloxetine and Ondansetron.	Nausea/vomiting [MD90]	[38]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Duloxetine and Bupropion.	Nicotine use disorder [6C4A]	[38]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Duloxetine and Sibutramine.	Obesity [5B80-5B81]	[50]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Duloxetine and Lorcaserin.	Obesity [5B80-5B81]	[51]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Duloxetine and Dexfenfluramine.	Obesity [5B80-5B81]	[14]
Propylhexedrine	DMTBW2O	Moderate	Additive hypertensive effects by the combination of Duloxetine and Propylhexedrine.	Obesity [5B80-5B81]	[18]
Metolazone	DMB39LO	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Metolazone.	Oedema [MG29]	[30]
Polythiazide	DMCH80F	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Polythiazide.	Oedema [MG29]	[30]
Urea	DMUK75B	Moderate	Increased risk of hyponatremia by the combination of Duloxetine and Urea.	Oesophagitis [DA24]	[30]
Levomethadyl Acetate	DM06HG5	Moderate	Additive serotonergic effects by the combination of Duloxetine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[31]
Rofecoxib	DM3P5DA	Moderate	Decreased metabolism of Duloxetine caused by Rofecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[25]
Diclofenac	DMPIHLS	Moderate	Increased risk of bleeding by the combination of Duloxetine and Diclofenac.	Osteoarthritis [FA00-FA05]	[22]
Naproxen	DMZ5RGV	Moderate	Increased risk of bleeding by the combination of Duloxetine and Naproxen.	Osteoarthritis [FA00-FA05]	[22]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Duloxetine caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[17]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Duloxetine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[25]
Pentazocine	DM1XBHS	Major	Additive serotonergic effects by the combination of Duloxetine and Pentazocine.	Pain [MG30-MG3Z]	[14]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Duloxetine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[52]
Butorphanol	DM5KYPJ	Moderate	Additive CNS depression effects by the combination of Duloxetine and Butorphanol.	Pain [MG30-MG3Z]	[31]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Duloxetine and Oxymorphone.	Pain [MG30-MG3Z]	[31]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Duloxetine and Aspirin.	Pain [MG30-MG3Z]	[29]
Etodolac	DM6WJO9	Moderate	Increased risk of bleeding by the combination of Duloxetine and Etodolac.	Pain [MG30-MG3Z]	[22]
Diflunisal	DM7EN8I	Moderate	Increased risk of bleeding by the combination of Duloxetine and Diflunisal.	Pain [MG30-MG3Z]	[22]
Ibuprofen	DM8VCBE	Moderate	Increased risk of bleeding by the combination of Duloxetine and Ibuprofen.	Pain [MG30-MG3Z]	[22]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Duloxetine and Levorphanol.	Pain [MG30-MG3Z]	[31]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Duloxetine and Dezocine.	Pain [MG30-MG3Z]	[31]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Duloxetine and Nalbuphine.	Pain [MG30-MG3Z]	[31]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Duloxetine and Buprenorphine.	Pain [MG30-MG3Z]	[31]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Duloxetine and Hydrocodone.	Pain [MG30-MG3Z]	[31]
Piroxicam	DMTK234	Moderate	Increased risk of bleeding by the combination of Duloxetine and Piroxicam.	Pain [MG30-MG3Z]	[22]
Oxycodone	DMXLKHV	Moderate	Additive CNS depression effects by the combination of Duloxetine and Oxycodone.	Pain [MG30-MG3Z]	[31]
Thiabendazole	DM7YCK3	Moderate	Decreased metabolism of Duloxetine caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[25]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Duloxetine and Safinamide.	Parkinsonism [8A00]	[15]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Duloxetine and Rasagiline.	Parkinsonism [8A00]	[15]
Dopamine	DMPGUCF	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Dopamine.	Parkinsonism [8A00]	[18]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Duloxetine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[53]
Ranitidine	DM0GUSX	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Ranitidine.	Peptic ulcer [DA61]	[18]
Esomeprazole	DM7BN0X	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Esomeprazole.	Peptic ulcer [DA61]	[18]
Famotidine	DMRL3AB	Minor	Decreased absorption of Duloxetine due to altered gastric pH caused by Famotidine.	Peptic ulcer [DA61]	[18]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Duloxetine and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[22]
Bromfenac	DMKB79O	Moderate	Increased risk of bleeding by the combination of Duloxetine and Bromfenac.	Postoperative inflammation [1A00-CA43]	[22]
Ritodrine	DM4V6RL	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Ritodrine.	Preterm labour/delivery [JB00]	[18]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Duloxetine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[18]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Duloxetine caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[54]
Levomepromazine	DMIKFEL	Moderate	Decreased metabolism of Duloxetine caused by Levomepromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[18]
Fluphenazine	DMIT8LX	Moderate	Decreased metabolism of Duloxetine caused by Fluphenazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[18]
Triflupromazine	DMKFQJP	Moderate	Decreased metabolism of Duloxetine caused by Triflupromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[18]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Duloxetine and Epoprostenol.	Pulmonary hypertension [BB01]	[22]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Duloxetine and Iloprost.	Pulmonary hypertension [BB01]	[22]
Meloxicam	DM2AR7L	Moderate	Increased risk of bleeding by the combination of Duloxetine and Meloxicam.	Rheumatoid arthritis [FA20]	[22]
Sulindac	DM2QHZU	Moderate	Increased risk of bleeding by the combination of Duloxetine and Sulindac.	Rheumatoid arthritis [FA20]	[22]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Duloxetine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[18]
Oxaprozin	DM9UB0P	Moderate	Increased risk of bleeding by the combination of Duloxetine and Oxaprozin.	Rheumatoid arthritis [FA20]	[22]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of bleeding by the combination of Duloxetine and Flurbiprofen.	Rheumatoid arthritis [FA20]	[22]
Fenoprofen	DML5VQ0	Moderate	Increased risk of bleeding by the combination of Duloxetine and Fenoprofen.	Rheumatoid arthritis [FA20]	[22]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Duloxetine and Leflunomide.	Rheumatoid arthritis [FA20]	[38]
Tolmetin	DMWUIJE	Moderate	Increased risk of bleeding by the combination of Duloxetine and Tolmetin.	Rheumatoid arthritis [FA20]	[22]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Duloxetine caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[18]
Mesoridazine	DM2ZGAN	Moderate	Decreased metabolism of Duloxetine caused by Mesoridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Thioridazine	DM35M8J	Major	Decreased metabolism of Duloxetine caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[55]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Duloxetine caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[56]
Haloperidol	DM96SE0	Moderate	Decreased metabolism of Duloxetine caused by Haloperidol mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Perphenazine	DMA4MRX	Moderate	Decreased metabolism of Duloxetine caused by Perphenazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Chlorpromazine	DMBGZI3	Moderate	Decreased metabolism of Duloxetine caused by Chlorpromazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Trifluoperazine	DMKBYWI	Moderate	Decreased metabolism of Duloxetine caused by Trifluoperazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Risperidone	DMN6DXL	Moderate	Decreased metabolism of Duloxetine caused by Risperidone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[18]
Pimozide	DMW83TP	Major	Decreased metabolism of Duloxetine caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[38]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of bleeding by the combination of Duloxetine and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[29]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Duloxetine and Fentanyl.	Sensation disturbance [MB40]	[14]
Sufentanil	DMU7YEL	Major	Additive serotonergic effects by the combination of Duloxetine and Sufentanil.	Sensation disturbance [MB40]	[14]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[33]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Duloxetine caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[33]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Duloxetine and Naltrexone.	Substance abuse [6C40]	[57]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Duloxetine and Caplacizumab.	Thrombocytopenia [3B64]	[22]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Duloxetine and Apixaban.	Thrombosis [DB61-GB90]	[22]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Duloxetine and Cangrelor.	Thrombosis [DB61-GB90]	[22]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Duloxetine and Brilinta.	Thrombosis [DB61-GB90]	[22]
Clopidogrel	DMOL54H	Moderate	Increased risk of bleeding by the combination of Duloxetine and Clopidogrel.	Thrombosis [DB61-GB90]	[22]
Cabozantinib	DMIYDT4	Moderate	Increased risk of bleeding by the combination of Duloxetine and Cabozantinib.	Thyroid cancer [2D10]	[22]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Duloxetine and Tizanidine.	Tonus and reflex abnormality [MB47]	[58]
Nalidixic acid	DMRM0JV	Moderate	Decreased metabolism of Duloxetine caused by Nalidixic acid mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[25]
Chlorpheniramine	DM5URA2	Moderate	Decreased metabolism of Duloxetine caused by Chlorpheniramine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[18]
Methdilazine	DMAUHQX	Moderate	Decreased metabolism of Duloxetine caused by Methdilazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Moderate	Decreased metabolism of Duloxetine caused by Trimeprazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[18]
Xylometazoline	DMKV32D	Moderate	Increased risk of rapid heart rate by the combination of Duloxetine and Xylometazoline.	Vasomotor/allergic rhinitis [CA08]	[18]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Duloxetine and Betrixaban.	Venous thromboembolism [BD72]	[22]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Duloxetine caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[18]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Duloxetine caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[18]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Duloxetine caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[25]
-----------


⏷ Show the Full List of 254 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Aminoethanoic acid	E00025	750	Buffering agent; Disintegrant; Lyophilization aid
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propylene glycol 1-(2-methylbutyrate)	E00540	23497922	Other agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dibutyl sebacate	E00160	7986	Plasticizing agent
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 407	E00646	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 37 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Duloxetine 20 mg capsule	20 mg	Delayed Release Oral Capsule	Oral
Duloxetine 60 mg capsule	60 mg	Delayed Release Oral Capsule	Oral
Duloxetine 30 mg capsule	30 mg	Delayed Release Oral Capsule	Oral
Duloxetine 40 mg capsule	40 mg	Delayed Release Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 202).
2	Duloxetine FDA Label
3	Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
8	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
9	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
10	Duloxetine Protects Human Neuroblastoma Cells from Oxidative Stress-Induced Cell Death Through Akt/Nrf-2/HO-1 Pathway. Neurochem Res. 2018 Feb;43(2):387-396. doi: 10.1007/s11064-017-2433-3. Epub 2017 Nov 13.
11	Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
12	Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Am J Psychiatry. 2007 Jul;164(7):1121-2. doi: 10.1176/ajp.2007.164.7.1121a.
13	Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Toxicol In Vitro. 2018 Mar;47:63-71.
14	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
15	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
16	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
19	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
20	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
21	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
22	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
23	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
24	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
25	Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
26	Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
27	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
29	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
30	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
31	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
32	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
33	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34	Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
35	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
36	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
37	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
38	Canadian Pharmacists Association.
39	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
40	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
42	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
44	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
45	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
46	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
47	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
48	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
49	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
50	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
51	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
52	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
53	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
55	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
56	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
57	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
58	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.